MX2007012222A - Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles. - Google Patents

Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.

Info

Publication number
MX2007012222A
MX2007012222A MX2007012222A MX2007012222A MX2007012222A MX 2007012222 A MX2007012222 A MX 2007012222A MX 2007012222 A MX2007012222 A MX 2007012222A MX 2007012222 A MX2007012222 A MX 2007012222A MX 2007012222 A MX2007012222 A MX 2007012222A
Authority
MX
Mexico
Prior art keywords
disorders associated
immune disorders
methods
mutant molecules
soluble ctla4
Prior art date
Application number
MX2007012222A
Other languages
English (en)
Inventor
James Rusnak
David Hagerty
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2007012222A publication Critical patent/MX2007012222A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente invencion proporciona el uso de moleculas mutantes de CTLA4 solubles que se aglutinan con mayor afinidad hacia el antigeno de CD80 y/o CD86 que el CTLA4 del tipo silvestre o el CTLA4Ig no mutado en el tratamiento de trastornos inmunes asociados con el trasplante de injerto.
MX2007012222A 2005-04-06 2006-04-05 Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles. MX2007012222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66877405P 2005-04-06 2005-04-06
PCT/US2006/012648 WO2006108035A1 (en) 2005-04-06 2006-04-05 Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules

Publications (1)

Publication Number Publication Date
MX2007012222A true MX2007012222A (es) 2007-12-06

Family

ID=36694299

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012222A MX2007012222A (es) 2005-04-06 2006-04-05 Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.

Country Status (25)

Country Link
US (2) US7482327B2 (es)
EP (1) EP1868635B1 (es)
JP (1) JP2008535841A (es)
KR (1) KR101235484B1 (es)
CN (1) CN101198347A (es)
AR (1) AR055052A1 (es)
AU (1) AU2006231622B2 (es)
BR (1) BRPI0608144A2 (es)
CA (1) CA2603970A1 (es)
CY (1) CY1119145T1 (es)
DK (1) DK1868635T3 (es)
EA (1) EA013122B1 (es)
ES (1) ES2634260T3 (es)
HR (1) HRP20171121T8 (es)
IL (1) IL186189A (es)
LT (1) LT1868635T (es)
ME (1) ME02930B (es)
MX (1) MX2007012222A (es)
NO (1) NO342966B1 (es)
NZ (2) NZ561655A (es)
PL (1) PL1868635T3 (es)
PT (1) PT1868635T (es)
RS (1) RS56138B1 (es)
SI (1) SI1868635T1 (es)
WO (1) WO2006108035A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MX2007012222A (es) * 2005-04-06 2007-12-06 Bristol Myers Squibb Co Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
EP2612868B1 (en) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
KR20110074850A (ko) * 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
EP2365823B1 (en) * 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US20100297123A1 (en) * 2009-05-15 2010-11-25 Garrison Fathman C Combination therapy to inhibit t cell effector function
KR20130049775A (ko) 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
CA2810631A1 (en) 2010-09-08 2012-03-15 Yeda Research And Development Co. Ltd. An immunosuppressive drug combination for a stable and long term engraftment
CN103282047B (zh) 2010-09-08 2016-08-24 耶达研究及发展有限公司 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
CN103930130B (zh) 2011-09-08 2016-07-06 耶达研究及发展有限公司 抗第三方中央型记忆t细胞、其产生方法以及其在移植和疾病治疗中的应用
JP6163158B2 (ja) 2011-10-13 2017-07-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ４０ｌに拮抗する抗体ポリペプチド
SG11201506919XA (en) * 2013-03-28 2015-10-29 Bristol Myers Squibb Co Methods for identifying patients at risk for costimulation blockade resistant rejection
CN104673822A (zh) * 2013-11-27 2015-06-03 深圳先进技术研究院 一种重组载体及其制备方法和应用
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
MX2016011102A (es) 2014-03-19 2017-01-26 Bristol Myers Squibb Co Metodos para tratar rechazo al trasplante usando un anticuerpo de dominio dirigido contra cd40l.
KR20240046641A (ko) 2015-04-17 2024-04-09 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 친화성을 갖는 면역조절 단백질
CA2991690A1 (en) 2015-07-16 2017-01-19 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory t cells and use of same in immunotherapy
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
CN110392736A (zh) 2017-01-18 2019-10-29 耶达研究及发展有限公司 遗传修饰的反抑细胞及其在免疫治疗中的用途
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
MA50360A (fr) 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
US11925640B2 (en) 2018-06-22 2024-03-12 Mayo Foundation For Medical Education And Research Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality
WO2020010259A1 (en) * 2018-07-06 2020-01-09 Mayo Foundation For Medical Education And Research Methods and materials for improving transplant outcomes
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
CN115089718A (zh) * 2021-11-30 2022-09-23 杭州瑞普晨创科技有限公司 用于异种移植的免疫抑制剂组合和免疫抑制方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE122007000078I2 (de) 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU2002243905B2 (en) * 2001-01-26 2007-11-08 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
PL204899B1 (pl) * 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
WO2003088991A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
ES2354610T5 (es) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
WO2004058800A2 (en) 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
MX2007012222A (es) * 2005-04-06 2007-12-06 Bristol Myers Squibb Co Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.

Also Published As

Publication number Publication date
SI1868635T1 (sl) 2017-07-31
HRP20171121T1 (hr) 2017-10-06
DK1868635T3 (en) 2017-09-11
PT1868635T (pt) 2017-07-27
ES2634260T3 (es) 2017-09-27
EA200702180A1 (ru) 2008-10-30
AR055052A1 (es) 2007-08-01
CY1119145T1 (el) 2018-02-14
RS56138B1 (sr) 2017-10-31
NZ576434A (en) 2010-06-25
US20070009511A1 (en) 2007-01-11
HRP20171121T8 (hr) 2017-11-03
NO342966B1 (no) 2018-09-10
KR20070119728A (ko) 2007-12-20
IL186189A (en) 2015-11-30
NZ561655A (en) 2010-01-29
EP1868635A1 (en) 2007-12-26
LT1868635T (lt) 2017-07-10
BRPI0608144A2 (pt) 2009-11-17
JP2008535841A (ja) 2008-09-04
AU2006231622B2 (en) 2012-07-05
KR101235484B1 (ko) 2013-02-22
CA2603970A1 (en) 2006-10-12
US7482327B2 (en) 2009-01-27
IL186189A0 (en) 2008-01-20
EA013122B1 (ru) 2010-02-26
NO20075078L (no) 2008-01-04
ME02930B (me) 2018-04-20
WO2006108035A1 (en) 2006-10-12
CN101198347A (zh) 2008-06-11
US20100041602A1 (en) 2010-02-18
EP1868635B1 (en) 2017-05-17
AU2006231622A1 (en) 2006-10-12
PL1868635T3 (pl) 2017-10-31

Similar Documents

Publication Publication Date Title
MX2007012222A (es) Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
GEP20053658B (en) Soluble CTLA4 Mutant Molecules and Uses Thereof
MX344971B (es) Anticuerpos anti-ctla4 humanizados.
IL184617A0 (en) Dr5 antibodies and uses thereof
PH12020500078A1 (en) Anti-ctla-4 antibodies and uses thereof
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
WO2007056539A3 (en) Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
MX2007001638A (es) Proteinas de fusion del dominio de unión.
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY165273A (en) Anti-cd48 antibodies and uses thereof
WO2007056540A3 (en) Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
GEP20166454B (en) Sclerostin binding agents
WO2008094254A3 (en) Methods and compositions for the treatment of cancer or other diseases
NZ599875A (en) Human il-23 antigen binding proteins
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
MY149630A (en) Antibodies against amyloid-beta peptide
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MXPA05012832A (es) Punto terminal terapeutico sustituto para inmunoterapia de enfermedad basada en anti-ctla-4.
TW200736275A (en) Methods and compositions for treating allergic diseases
SG10201407938TA (en) Agents for treating disease
MX2010002773A (es) Antigenos mutantes de gas57 y anticuerpos de gas57.
MX2011002488A (es) Vacuna que comprende proteina nmb0964 de neisseria meningitidis.
WO2009023055A3 (en) Blockade of the inhibitory qa-1-cd94/nkg2a pathway for treatment of autoimmune disease

Legal Events

Date Code Title Description
FG Grant or registration